Compare · OCDX vs ORKA
OCDX vs ORKA
Side-by-side comparison of Ortho Clinical Diagnostics Holdings plc (OCDX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OCDX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- OCDX is the larger of the two at $4.08B, about 1.1x ORKA ($3.78B).
- ORKA has hit the wire 11 times in the past 4 weeks while OCDX has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 8 for OCDX).
- Company
- Ortho Clinical Diagnostics Holdings plc
- Oruka Therapeutics Inc.
- Price
- $17.64+0.46%
- $75.44-1.24%
- Market cap
- $4.08B
- $3.78B
- 1M return
- -
- +69.59%
- 1Y return
- -
- +631.01%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 11
- Recent ratings
- 8
- 11
Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
Latest OCDX
- SEC Form 15-12B filed by Ortho Clinical Diagnostics Holdings plc
- SEC Form 4: Iskra Michael S. returned 150,000 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Busky Joseph M
- SEC Form 4: Schlesinger Michael A. returned 87,637 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Palaniappan Chockalingam
- SEC Form 4: Yates Robert Clifton returned 323,880 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Smith Christopher M returned 367,360 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Dilsaver Evelyn S returned 5,200 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Mac Mahon Thomas P returned 141,853 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Labrum Ronald K returned 109,985 units of Ordinary Shares to the company, closing all direct ownership in the company
Latest ORKA
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
- Oruka Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Goncalves Joana